TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[TPI Reports First Quarter Fiscal Year 2012 Financial Results CHENGDU, China, Nov. 14, 2011 Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter of Fiscal Year 2012. First quarter fiscal year 2012 ending September 30, 2011] [Tianyin Pharmaceutical, Incorporated First Quarter 2012 Annual Financial Results Conference Call November 14, 2011 Operator: Dr. James Tong: 1 Sales for the quarter ended September 30, 2011 was $17.5 million, a decrease of 20.5% as compared to $22 million for the quarter ended September 30th, 2010. The sales decrease was mainly due to the pricing pressure on our generic pharmaceuticals,] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 14, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. 000-52236 Delaware of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o o Item 7.01. Regulation FD Disclosure Description]